Cervical carcinoma cells transfected with the CD80 gene elicit a primary cytotoxic T lymphocyte response specific for HPV 16 E7 antigens

Cancer Gene Therapy

Volumn 4, Issue 6, 1997, Pages 377-382

  Kaufmann, Andreas M ^a   Gissmann, Lutz ^a   Schreckenberger, Carola ^a   Qiao, Liang ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

CD80; Cervical carcinoma; Costimulation; Human papillomavirus; Peptide epitopes; T lymphocytes

Indexed keywords

B7 ANTIGEN; HLA A ANTIGEN; ONCOGENE PROTEIN E7, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; RECOMBINANT PROTEIN;

ARTICLE; B LYMPHOCYTE; BIOSYNTHESIS; CELL CULTURE; CELL LINE; COCULTURE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; EPSTEIN BARR VIRUS; FEMALE; GENE THERAPY; GENETIC TRANSFECTION; GENETICS; HUMAN; IMMUNOLOGY; METHODOLOGY; PAPILLOMA VIRUS; RADIATION EXPOSURE; T LYMPHOCYTE; UTERINE CERVIX TUMOR;

ANTIGENS, CD80; B-LYMPHOCYTES; CELL LINE, TRANSFORMED; CELLS, CULTURED; COCULTURE TECHNIQUES; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GENE THERAPY; HERPESVIRUS 4, HUMAN; HLA-A ANTIGENS; HUMANS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; RECOMBINANT PROTEINS; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; TUMOR CELLS, CULTURED; UTERINE CERVICAL NEOPLASMS;

EID: 0031262740     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Chen LP, Ashe S, Brady WA, et al. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell. 1992;71: 1093-1102.
2. Chen LP, McGowan P, Ashe S, et al. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med. 1994;179:523-532.
3. Townsend SE, Allison JP. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science. 1993;259:368-370.
4. Baskar S, Ostrand-Rosenberg S, Nabavi N, Nadler LM, Freeman GJ, Glimcher LH. Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc Natl Acad Sci USA. 1993;90:5687-5690.
5. Azuma M, Cayabyab M, Buck D, Phillips JH, Lanier LL. CD28 stimulation with B7 costimulates primary allogeneic proliferative responses and cytotoxicity mediated by small resting T lymphocytes. J Exp Med. 1992;175:353-360.
6. Döhring C, Angman L, Spagnoli G, Lanzavecchia A. T-helper- and accessory-cell-dependent cytotoxic responses to human tumor cells transfected with a B7 retroviral vector. Int J Cancer. 1994;57:754-759.
7. + T lymphocytes. Cytokines Mol Ther. 1995;1:211-221.
8. Kaufmann AM, Gissmann L, Street D, et al. Expression of CD80 enhances immunogenicity of cervical cancer cells in vitro. Cellular Immunol. 1996;169:246-251.
9. zur Hausen, H. Human papillomaviruses in the pathogenesis of anogenital cancer. Virology. 1991;184:9-13.
10. Koutsky LA, Galloway DA, Holmes KK. Epidemiology of genital human papillomavirus infection. Epidemiol Rev. 1988;10:122-163.
11. Seedorf K, Oltersdorf T, Krammer G, Röwekamp W. Identification of early proteins of the human papillomaviruses type 16 (HPV16) and type 18 (HPV18) in cervical carcinoma cells. EMBO J. 1987;6:139-144.
12. Dyson N, Howley PM, Münger KM, Harlow E. The human papillomavirus-16 E7 protein is able to bind to the retinoblastoma gene product. Science. 1989;243:934-937.
13. Sadovnikova E, Zhu X, Collins SM, et al. Limitations of predictive motifs revealed by cytotoxic T lymphocyte epitope mapping of the human papilloma virus E7 protein. Int Immunol. 1995;6:289-296.
14. Feltkamp MCW, Smits HL, Vierboom MPM, et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol. 1993;23:2242-2249.
15. Chen LP, Thomas EK, Hu SL, et al. Human papillomavirus 16 nucleoprotein E7 is a tumor rejection antigen. Proc Natl Acad Sci USA. 1991;88:110-114.
16. Kast WM, Brandt RMP, Sidney J, et al. Role of HLA-A motifes in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J Immunol. 1994;152:3904-3912.
17. Ressing ME, Sette A, Brandt RMP, et al. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J Immunol. 1995;154:5934-5943.
18. Jochmus-Kudielka I, Gissmann L. Expression of human papillomavirus type 16 proteins in Escherichia coli and their use as antigens in serological tests. In: Alitalo KK, Huhtala M-L, Knowles J, Vaheri A, eds. Recombinant Systems in Protein Expression. New York: Elsevier Science Publishers B. V. (Biomedical Division); 1990:87-93.
19. + T cells binds very tightly to the restricting class I major histocompatibility complex on intact cells but not to the purified class I protein. Proc Natl Acad Sci USA. 1991;88:11276-11280.
20. Elliot BE, Carlow DA, Rodricks A-M, Wade A. Perspectives on the role of MHC antigens in normal and malignant cell development. Adv Cancer Res. 1989;53:181-245.
21. Restifo NP, Esquivel F, Kawakami Y, et al. Identification of human cancers deficient in antigen processing. J Exp Med. 1993;177:265-272.
22. Cavallo F, Martin-Fontecha A, Bellone M, et al. Coexpression of B7-1 and ICAM-I on tumors is required for rejection and the establishment of a memory response. Eur J Immunol. 1995;25:1154-1162.
23. Schirren CA, Volpel H, Meuer SC. Adhesion molecules on freshly recovered T leukemias promote tumor-directed lympholysis. Blood. 1992;79:138-143.
24. Street D, Kaufmann AM, Vaughan A, et al. Interferon γ enhances susceptibility of cervical cancer cells to lysis by tumor-specific cytotoxic T cells. Gynecologic Oncology. 1997;65:265-272.
25. Ressing ME, van Driel WJ, Cells E, et al. Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A*0201-restricted E7-encoded epitope. Cancer Res. 1996;56:582-588.